LifeStance Health Group downgraded by TD Cowen with a new price target
$LFST
Medical/Nursing Services
Health Care
TD Cowen downgraded LifeStance Health Group from Outperform to Market Perform and set a new price target of $9.00 from $8.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/8/2025 | $9.00 | Overweight | KeyBanc Capital Markets |
| 4/3/2025 | $8.00 | Buy | Canaccord Genuity |
| 12/16/2024 | $10.00 | Neutral → Buy | Goldman |
| 1/3/2024 | $7.00 | Underweight | Barclays |
| 5/15/2023 | $8.00 → $9.00 | Outperform → Market Perform | TD Cowen |
| 1/6/2023 | $8.00 | Equal-Weight → Overweight | Morgan Stanley |
| 11/7/2022 | $7.25 | Buy | Jefferies |
| 3/17/2022 | $19.00 → $10.00 | Buy → Neutral | UBS |
DEFA14A - LifeStance Health Group, Inc. (0001845257) (Filer)
DEF 14A - LifeStance Health Group, Inc. (0001845257) (Filer)
144 - LifeStance Health Group, Inc. (0001845257) (Subject)
SCOTTSDALE, Ariz., April 21, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ:LFST), one of the nation's largest providers of outpatient mental health care, will issue its first quarter 2025 earnings release before the market opens on Wednesday, May 7, 2025. LifeStance will host a live earnings conference call to discuss first quarter results on May 7, 2025, at 8:30 a.m. Eastern Time. To participate in the call, please dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, and use conference ID 6060781, or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentations section of the LifeStance Investor R
Less Than Half of Respondents Consistently Seek Professional Guidance for Self-Diagnosed Conditions, Reinforcing the Need for Increased Access to Evidence-Based Mental Health Care SCOTTSDALE, Ariz., April 15, 2025 /PRNewswire/ -- A LifeStance Health survey released today reveals the profound impact of social media on Americans' mental health and relationships, stemming from the prevalence of an "always-on" connectivity culture and a growing reliance on online mental health content, despite concerns about misinformation and credibility. The LifeStance survey, "Navigating Menta
Ryan McGroarty to Become Chief Financial Officer SCOTTSDALE, Ariz., Feb. 27, 2025 /PRNewswire/ -- LifeStance Health Group, Inc. ("LifeStance" or the "Company") (NASDAQ:LFST), one of the nation's largest providers of outpatient mental health care, today announced that its Board of Directors has appointed Dave Bourdon as the Company's new Chief Executive Officer. Bourdon, who joined LifeStance as Chief Financial Officer in 2022, is succeeding Ken Burdick, who is retiring from his role as CEO and will assume the role of Executive Chairman. Bourdon has also been appointed to serve on the Board of Directors. In addition, Ryan McGroarty has been appointed to serve as the company's new Chief Financ
4 - LifeStance Health Group, Inc. (0001845257) (Issuer)
4 - LifeStance Health Group, Inc. (0001845257) (Issuer)
4 - LifeStance Health Group, Inc. (0001845257) (Issuer)
SCOTTSDALE, Ariz., April 21, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ:LFST), one of the nation's largest providers of outpatient mental health care, will issue its first quarter 2025 earnings release before the market opens on Wednesday, May 7, 2025. LifeStance will host a live earnings conference call to discuss first quarter results on May 7, 2025, at 8:30 a.m. Eastern Time. To participate in the call, please dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, and use conference ID 6060781, or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentations section of the LifeStance Investor R
Ryan McGroarty to Become Chief Financial Officer SCOTTSDALE, Ariz., Feb. 27, 2025 /PRNewswire/ -- LifeStance Health Group, Inc. ("LifeStance" or the "Company") (NASDAQ:LFST), one of the nation's largest providers of outpatient mental health care, today announced that its Board of Directors has appointed Dave Bourdon as the Company's new Chief Executive Officer. Bourdon, who joined LifeStance as Chief Financial Officer in 2022, is succeeding Ken Burdick, who is retiring from his role as CEO and will assume the role of Executive Chairman. Bourdon has also been appointed to serve on the Board of Directors. In addition, Ryan McGroarty has been appointed to serve as the company's new Chief Financ
SCOTTSDALE, Ariz., Feb. 06, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ:LFST), one of the nation's largest providers of outpatient mental health care, will issue its fourth quarter and full year 2024 earnings release before the market opens on Thursday, February 27, 2025. LifeStance will host a live earnings conference call to discuss fourth quarter and full year results on February 27, 2025, at 8:30 a.m. Eastern Time. To participate in the call, please dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, and use conference ID 4372752, or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentati
SCOTTSDALE, Ariz., March 12, 2024 /PRNewswire/ -- LifeStance Health, one of the nation's largest providers of virtual and in-person outpatient mental healthcare, today announced that Dr. Teresa DeLuca has joined the company's board of directors. Dr. DeLuca is a psychiatrist and accomplished physician executive with over 20 years of leadership experience, having held senior executive leadership roles at Magellan Health, Humana and Walgreens, and brings extensive healthcare operations and clinical management expertise to LifeStance's board of directors. "Dr. DeLuca's background
SCOTTSDALE, Ariz., Jan. 19, 2024 /PRNewswire/ -- LifeStance Health, one of the nation's largest providers of virtual and in-person outpatient mental healthcare, today announced that Dr. Ujjwal Ramtekkar will join the company as Chief Medical Officer, effective January 22, 2024. He will lead all clinical services, ensuring that LifeStance's psychiatric and psychotherapy clinicians are enabled to deliver high-quality, personalized patient care that meets and exceeds professional standards. "Dr. Ramtekkar is an experienced physician executive with a demonstrated track record of d
SCOTTSDALE, Ariz., Nov. 3, 2022 /PRNewswire/ -- LifeStance Health (NASDAQ:LFST), one of the nation's largest providers of outpatient mental healthcare, today announced that effective November 10, 2022, J. Michael Bruff, currently Chief Financial Officer, will take on a new role as Business Transformation Officer. David Bourdon will join the company and succeed Bruff as Chief Financial Officer. Both executives will report directly to Ken Burdick, Chairman and Chief Executive Officer, LifeStance. During LifeStance's long-range planning process, the company's leadership team ide
KeyBanc Capital Markets initiated coverage of LifeStance Health Group with a rating of Overweight and set a new price target of $9.00
Canaccord Genuity initiated coverage of LifeStance Health Group with a rating of Buy and set a new price target of $8.00
Goldman upgraded LifeStance Health Group from Neutral to Buy and set a new price target of $10.00
SC 13G/A - LifeStance Health Group, Inc. (0001845257) (Subject)
SC 13G/A - LifeStance Health Group, Inc. (0001845257) (Subject)
SC 13G/A - LifeStance Health Group, Inc. (0001845257) (Subject)